{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:21:50Z","timestamp":1770139310508,"version":"3.49.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To describe the characteristics of patients hospitalized with COVID-19 (including their long-term at-home medication use), and compare them with regard to the course of the disease. To assess the association between renin\u2013angiotensin system inhibitors (RASIs) and disease progression and critical outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>All consecutive hospitalized patients with laboratory-confirmed COVID-19 in a university hospital in Amiens (France) were included in this study. The primary composite endpoint was admission to an intensive care unit (ICU) or death before ICU admission. Univariable and multivariable logistic regression models were used to identify factors associated with the composite endpoint. Between 28 February 2020 and 30 March 2020, a total of 499 local patients tested positive for SARS-CoV-2. Of these, 231 were not hospitalized {males 33%; median [interquartile range (IQR)] age: 44 (32\u201354)}, and 268 were hospitalized [males 58%; median (IQR) age: 73 (61\u201384)]. A total of 116 patients met the primary endpoint: 47 died before ICU admission, and 69 were admitted to the ICU. Patients meeting the primary endpoint were more likely than patients not meeting the primary endpoint to have coronary heart disease and to have been taking RASIs; however, the two subsets of patients did not differ with regard to median age. After adjustment for other associated variables, the risk of meeting the composite endpoint was 1.73 times higher (odds ratio 1.73, 95% confidence interval 1.02\u20132.93) in patients treated at baseline with a RASI than in patients not treated with this drug class. This association was confirmed when the analysis was restricted to patients treated with antihypertensive agents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We highlighted a potential safety signal for RASIs, the long-term use of which was independently associated with a higher risk of severe COVID-19 and a poor outcome. Due to the widespread use of this important drug class, formal proof based on clinical trials is needed to better understand the association between RASIs and complications of COVID-19.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaa062","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T11:09:31Z","timestamp":1590664171000},"page":"426-434","source":"Crossref","is-referenced-by-count":34,"title":["Association between renin\u2013angiotensin system inhibitors and COVID-19 complications"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5384-9006","authenticated-orcid":false,"given":"Sophie","family":"Liabeuf","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France"},{"name":"MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Moragny","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef","family":"Bennis","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France"},{"name":"MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Batteux","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France"},{"name":"MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Brochot","sequence":"additional","affiliation":[{"name":"Department of Virology, Amiens University Medical Center, Amiens, France"},{"name":"EA 4294, Jules Verne University of Picardie, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Luc","family":"Schmit","sequence":"additional","affiliation":[{"name":"EA 4294, Jules Verne University of Picardie, Amiens, France"},{"name":"Infectious Diseases Department, University Hospital, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Lanoix","sequence":"additional","affiliation":[{"name":"EA 4294, Jules Verne University of Picardie, Amiens, France"},{"name":"Infectious Diseases Department, University Hospital, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Andrejak","sequence":"additional","affiliation":[{"name":"EA 4294, Jules Verne University of Picardie, Amiens, France"},{"name":"Department of Pneumology, University Hospital of Amiens-Picardie, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Ganry","sequence":"additional","affiliation":[{"name":"Epidemiology and Public Health Service, Amiens University Hospital, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Slama","sequence":"additional","affiliation":[{"name":"MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France"},{"name":"Intensive Care Department and BoReal study group, Amiens University Hospital, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Maizel","sequence":"additional","affiliation":[{"name":"MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France"},{"name":"Intensive Care Department and BoReal study group, Amiens University Hospital, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazine","family":"Mahjoub","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care Medicine, Amiens University Medical Center, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamel","family":"Masmoudi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Gras-Champel","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Amiens University Hospital, Amiens, France"},{"name":"MP3CV Laboratory, EA7517, Jules Verne University of Picardie, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"2021092108333650000_pvaa062-B1"},{"key":"2021092108333650000_pvaa062-B2","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72\u202f314 cases from the Chinese Center for Disease Control and Prevention","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"2021092108333650000_pvaa062-B3","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","author":"Verity","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021092108333650000_pvaa062-B4","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25860","article-title":"Clinical and demographic characteristics of patients dying from COVID-19 in Italy versus China","author":"Lippi","year":"2020","journal-title":"J Med Virol"},{"key":"2021092108333650000_pvaa062-B5","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"2021092108333650000_pvaa062-B6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"2021092108333650000_pvaa062-B7","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jama.2020.5394","article-title":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy","volume":"323","author":"Grasselli","year":"2020","journal-title":"JAMA"},{"key":"2021092108333650000_pvaa062-B8","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202002-0445OC","article-title":"COVID-19 with different severity: a multi-center study of clinical features","author":"Feng","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2021092108333650000_pvaa062-B9","doi-asserted-by":"crossref","first-page":"m1086","DOI":"10.1136\/bmj.m1086","article-title":"Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists","volume":"368","author":"Day","year":"2020","journal-title":"BMJ"},{"key":"2021092108333650000_pvaa062-B10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"2021092108333650000_pvaa062-B11","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"2021092108333650000_pvaa062-B12","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2021092108333650000_pvaa062-B13","article-title":"Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"2021092108333650000_pvaa062-B14","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2021225","article-title":"Cardiovascular disease, drug therapy, and mortality in Covid-19","author":"Mehra","year":"2020","journal-title":"N Engl J Med"},{"key":"2021092108333650000_pvaa062-B15","volume-title":"Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (nCoV) Infection is Suspected: Interim Guidance, 25 January 2020","year":"2020"},{"key":"2021092108333650000_pvaa062-B16","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.18632\/aging.103000","article-title":"Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis","volume":"12","author":"Wang","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"2021092108333650000_pvaa062-B17","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4683","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy","author":"Onder","year":"2020","journal-title":"JAMA"},{"key":"2021092108333650000_pvaa062-B18","doi-asserted-by":"crossref","first-page":"m1091","DOI":"10.1136\/bmj.m1091","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study","volume":"368","author":"Chen","year":"2020","journal-title":"BMJ"},{"key":"2021092108333650000_pvaa062-B19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41577-019-0160-5","article-title":"Immune mechanisms of hypertension","volume":"19","author":"Drummond","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"2021092108333650000_pvaa062-B20","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvaa097","article-title":"Hypertension, the renin\u2013angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19","author":"Kreutz","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2021092108333650000_pvaa062-B21","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin\u2013angiotensin\u2013aldosterone system blockers and the risk of Covid-19","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"2021092108333650000_pvaa062-B22","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1855","article-title":"Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)","author":"Mehta","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2021092108333650000_pvaa062-B23"},{"key":"2021092108333650000_pvaa062-B24","year":"2020"},{"key":"2021092108333650000_pvaa062-B25","doi-asserted-by":"crossref","first-page":"m1313","DOI":"10.1136\/bmj.m1313","article-title":"Drugs and the renin\u2013angiotensin system in covid-19","volume":"369","author":"Aronson","year":"2020","journal-title":"BMJ"},{"key":"2021092108333650000_pvaa062-B26","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2020.02.019","article-title":"Self-medication practices and their characteristics among French university students","author":"Gras","year":"2020","journal-title":"Therapie"},{"key":"2021092108333650000_pvaa062-B27","doi-asserted-by":"crossref","DOI":"10.1002\/oby.22831","article-title":"Lille Intensive Care COVID-19 and Obesity study group. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation","author":"Simonnet","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"2021092108333650000_pvaa062-B28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/ijo.2012.62","article-title":"Obesity and the risk and outcome of infection","volume":"37","author":"Huttunen","year":"2013","journal-title":"Int J Obes (Lond)"},{"key":"2021092108333650000_pvaa062-B29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rmed.2017.01.004","article-title":"The effects of obesity on lung volumes and oxygenation","volume":"124","author":"Littleton","year":"2017","journal-title":"Respir Med"},{"key":"2021092108333650000_pvaa062-B30","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1152\/japplphysiol.01267.2009","article-title":"Reduction of total lung capacity in obese men: comparison of total intrathoracic and gas volumes","volume":"108","author":"Watson","year":"2010","journal-title":"J Appl Physiol"},{"key":"2021092108333650000_pvaa062-B31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5114\/aoms.2016.58928","article-title":"Obesity and inflammation: the linking mechanism and the complications","volume":"13","author":"Ellulu","year":"2017","journal-title":"Arch Med Sci"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaa062\/33382677\/pvaa062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/5\/426\/40418846\/pvaa062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/5\/426\/40418846\/pvaa062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T08:34:53Z","timestamp":1632213293000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/7\/5\/426\/5856622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,6,12]]},"published-print":{"date-parts":[[2021,9,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa062","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9]]},"published":{"date-parts":[[2020,6,12]]}}}